虽然胰 高血糖 素样肽-1受体激动剂（GLP-1 RA）最初开发是用于治疗2型 糖尿病 ，但在研究中，研究人员发现，GLP-1 RA还能够帮助超重和肥胖患者减重，效果十分显著，并且与是否合并糖尿病无关。

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

In the US, 1 in 7 adults are experiencing some type of chronic kidney disease caused by diabetes. The new approval therefore allows doctor to prescribe Ozempic to lower the risk of kidney failure, ...

诺和诺德（Novo Nordisk）日前宣布，美国FDA已批准其重磅疗法Ozempic（司美格鲁肽，semaglutide），用于降低2型糖尿病合并慢性肾病（CKD）成年患者的肾病恶化、肾功能衰竭（终末期肾病）以及心血管疾病导致的死亡风险。根据新闻稿 ...

The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...

It showed that 1 mg Ozempic led to a 24 per cent reduced risk of worsening kidney disease and kidney failure (end-stage ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...